Eloxx Pharmaceuticals, Inc. (ELOX) intrinsic value & 10-year financials
Eloxx Pharmaceuticals, Inc. (ELOX) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 10 fiscal years revenue grew 74.2% a year to $0, with an average return on invested capital of 79.7%.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $13.03
- Market cap
- $160.9M
- Revenue (FY2025)
- $0
- Revenue growth (10-yr CAGR)
- 74.2%
- ROIC (10-yr avg)
- 79.7%
- Free cash flow (FY2025)
- —
ELOX 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $0 | -$6.0M | -$0.49 | — | — | 38.3% |
| FY2024 | $6.4M | -$3.1M | -$0.84 | — | -38.8% | 13.0% |
| FY2023 | $0 | -$17.1M | -$6.63 | — | — | 93.2% |
| FY2022 | — | -$36.1M | -$16.65 | -$31.9M | — | 283.5% |
| FY2021 | — | -$66.7M | -$38.15 | -$35.1M | — | 1337.2% |
| FY2020 | — | -$34.6M | — | — | — | -255.4% |
| FY2019 | — | -$50.9M | — | -$39.4M | — | -174.4% |
| FY2018 | — | -$47.2M | — | -$31.6M | — | -148.0% |
| FY2017 | — | -$21.2M | — | -$16.2M | — | -163.7% |
| FY2016 | $75.0K | -$8.3M | — | -$3.7M | -14926.6% | -226.8% |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Eloxx Pharmaceuticals, Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Eloxx Pharmaceuticals, Inc. has historically struggled to out-earn its cost of capital, averaging just 0.5% ROIC.
Eloxx Pharmaceuticals, Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, Eloxx Pharmaceuticals, Inc. is modeled at 15.0% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $-16.28 per share.